Who We Are

ATED Therapeutics, Ltd is dedicated to developing cutting-edge therapeutics and diagnostics for neurodegenerative diseases and then bringing them to the patient.

To realize this vision, we’ve forged a strategic partnership with Hebrew University in Israel and with the University of Rochester. Collaborating with prominent scientists at these institutions, we are transforming groundbreaking neuroscience research into commercially viable medical advancements.

Our initial work in neurodevelopmental disorders offered key insights, leading us to pursue Parkinson’s Disease.

Our focus is to bring the excellent work of Dr. Hermona Soreq and Dr. Daphne Atlas to the clinic, improving the diagnosis and treatment of Parkinson’s Disease.

Parkinson’s Disease

Parkinson’s Disease (PD) is the second fastest-growing neurodegenerative disease worldwide with a compounded annual growth rate of 11.3%.

According the Parkinson’s Foundation there are today more than 10M cases worldwide. This number will double within 10 years.

Select countries:

  • U.S. has nearly 1M cases and is adding 90,000 new cases per year.

  • Europe has 1.2M

  • China 3.5M

  • Mexico 500,000

Parkinson’s is primarily a movement-related neurodegenerative disorder. It is known for the loss of dopaminergic neurons in the part of the brain called the substantia nigra. It is distinguished by the accumulation and the aggregation of the protein alpha-synuclein, which forms dark staining cells called Lewy bodies. The molecular mechanisms leading to the disease may be due to several factors including oxidative stress, inflammation, dimer and trimer formation of the protein alpha-synuclein. Pollution may also play a role in the development of the disease.

Parkinson’s Disease: Diagnostics

ATED, in partnership with Dr. Hermona Soreq of Hebrew University, has developed a new rapid and accurate blood test for Parkinson’s Disease. This novel test measures transfer RNA fragments (tRF’s) in nucleated red blood cells, detecting the disease at its earliest stages—before major symptoms appear. Using a patented specific nucleotide sequence as a biomarker, we can detect early stage PD in both genetic and sporadic cases.

Currently, Parkinson’s is diagnosed by qualitative methods and only after significant (50%-70%) neuronal cell loss. Furthermore, 20%-25% of cases are currently misdiagnosed. By contrast, our tRNA test can be used at the earliest stage and can distinguish between PD and Frontal Temporal Dementia, Progressive Supranuclear Palsy and other neurodegenerative diseases

Our test enables early intervention and importantly tracks disease progression, offering new hope for timely and effective treatment. There is also the possibility of using the test for population screening as the disease is increasing rapidly.

Our tRNA blood test may also quantitatively measure the effectiveness of deep brain stimulation (DBS).

DBS is used to control the “off" periods in Parkinson’s patients who are not fully responding to their current medication. There are about 12,000 cases per year in the U.S.

Until now there has been no way to quantify the benefit of this procedure. Now there may be.

PD-tRFs decline in DBS-treated PD

Disease Modifying Drugs

Parkinson’s Disease: Therapeutics

No new drug has been developed to treat Parkinson’s in 50 years.

In collaboration with Dr. Daphne Atlas at Hebrew University, we have licensed SuperDopamide and SuperDopamine—novel therapies combining L-dopa with N-acetylcysteine (NAC) through a peptide bond. These drugs are disease modifying. Current drugs Carbidopa-Levodopa are replacement therapy.

In preclinical studies using the rat rotenone model of Parkinson’s, our drugs have demonstrated the ability to prevent alpha-synuclein aggregation, decrease oxidative stress, reduce inflammation, and slowed disease progression.

ATED is now preparing for Phase I clinical trials.